Back HIV/AIDS

HIV / AIDS

HIV Superinfection May Boost Viral Load but Does Not Worsen Disease Progression

Superinfection with a second strain of HIV may lead to a more rapid increase in plasma HIV RNA levels, but apparently does not contribute much to CD4 T-cell loss or disease progression, according to a study published in the September 24 edition of AIDS.

alt

HIV Pandemic Likely Originated in Kinshasa, Spread Via New Transportation Routes

Kinshasa, in what is now the Democratic Republic of Congo, was likely the focus of early HIV-1 transmission beginning in the 1920s, leading to the wider global pandemic starting in the 1960s as railroad and river transportation became more widely used, according to a study published in the October 3 edition of Science.

alt

FDA Approves Elvitegravir and Cobicistat Booster as Stand-alone Drugs

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences next-generation HIV integrase inhibitor elvitegravir (brand name Viteka) and pharmacoenhancer cobicistat (Tybost) as stand-alone agents to be used in combination antiretroviral therapy. The 2 drugs were already available as part of the Stribild single-tablet regimen.

alt

UCSF Announces New HIV PrEP Clinic and PrEPline Phone Consultation Service

The University of California at San Francisco has opened a new clinic to help address the unmet need for Truvada pre-exposure prophylaxis, better known as PrEP. In addition, the UCSF Clinician Consultation Center at San Francisco General Hospital has received CDC funding to operate PrEPline, a telephone consultation service to provide expert guidance to healthcare providers across the nation who wish to prescribe PrEP.

alt

Tenofovir Alafenamide Pill Matches Stribild, Gilead Will Seek Approval Soon

A new single-tablet regimen containing tenofovir alafenamide (TAF), elvitegravir, cobicistat, and emtricitabine worked as well as Stribild at 48 weeks in a pair of Phase 3 trials, but had less detrimental effects on the kidneys and bones, Gilead Sciences announced this week. These findings set the stage for evaluation by the U.S. Food and Drug Administration and European regulators.

alt

National Gay Men's HIV/AIDS Awareness Day: Half Untreated, Most Unaware of PrEP

Only 50% of gay and bi men diagnosed with HIV have started antiretroviral treatment and 42% have achieved undetectable viral load, according to a new Centers for Disease Control and Prevention (CDC) report released ahead of National Gay Men’s HIV/AIDS Awareness Day on September 27. A related survey from the Kaiser Family Foundation found that while gay and bi men see HIV as a top health issue, a majority do not get tested regularly and most do not know about pre-exposure prophylaxis, or PrEP.

alt

More iPrEx and OLE Data Published: Adherence Higher in U.S.

Participants enrolled at the U.S. study sites of the global iPrEx trial of Truvada pre-exposure prophylaxis (PrEP) achieved better adherence than those in other countries, reaching 90% in San Francisco, researchers reported in the September 16 advance edition of Journal of Acquired Immune Deficiency Syndromes. Findings from the iPrEx open-label extension (OLE) were also recently published.

alt